Q3 2023 Results
Company overview
Financial review
Conclusions
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
Neuroscience
Ophthalmology
BeovuⓇ - VEGF Inhibitor
NCT04278417 CONDOR (CRTH258D2301)
Indication
Diabetic retinopathy
Phase 3
Change from Baseline in BCVA
Phase
Patients
694
Primary
Outcome
Measures
Arms
Intervention
Arm 1: RTH258 (brolucizumab) 6 mg/50uL
Arm 2: Panretinal photocoagulation laser initial treatment followed with
additional PRP treatment as needed
Patients with proliferative diabetic retinopathy
Target
Patients
Readout
Milestone(s)
2024
Publication
TBD
Appendix
Innovation: Clinical trials
Oncology
Global Health
References
Abbreviations
Other
79 Investor Relations | Q3 2023 Results
1 NOVARTIS | Reimagining MedicineView entire presentation